News

Is $200 a share from Valeant enough after Allergan's strong Q3?

Valeant's hostile bid for Allergan may soon be on the rise. But after posting strong Q3 results earlier this week, some analysts say Allergan's value is, too.

Novartis gets 4% sales lift as 'growth products' make good on their label

Novartis' third-quarter profit may have gotten a large boost from the sale of its Idenix stake to Merck this summer, with cost cuts kicking in, too. But when it comes to top-line results that topped analysts' forecasts, the company has its own hot sellers to thank.

Pfizer's Q3 beats, but flat sales mean CEO Read needs a big move

Pfizer is popping the confetti on earnings that beat analysts' expectations, bolstered by sales of cancer drugs and growth in emerging markets. But as for that much-talked about deal with AstraZeneca? No word for now.

 

Big relief for Takeda, Lilly as judge slashes $9B Actos award by 99%

That scary $9 billion damages award a Louisiana jury slapped on Takeda and Eli Lilly earlier this year? A U.S. district judge slashed the bill by more than 99%, saying the new amount is the biggest award allowed under current law.

UPDATED: Looming trouble in Sanofi's diabetes biz turns up the heat on CEO

For another clue to the unrest on Sanofi's board, take a look at the third-quarter earnings report. There's not much red ink on the page, that's true: Sales are up 4%. Earnings up 8%. CEO Chris Viehbacher's growth platforms surged by 10%. The trouble lies in Viehbacher's canned quote.

Pharma's top 10 M&A deals of 2014's first half

Mergers and acquisitions have been non-stop this year, with lots of deals done, and some doozies that were unable to cross the finish line. Here we look at what's happened in the first half of...

Will buyers bite for Unipharm amid Russian M&A slow-down?

Drugmakers have been buying out OTC companies left and right lately. But would that demand apply to a Russia-focused consumer company, considering the recent slow-down in Russian investment? Unipharm is about to find out.

U.S. Attorney asks Novo Nordisk about plant in Denmark

Novo Nordisk says the U.S. Attorney in Massachusetts has subpoenaed it for information about potential manufacturing issues at a plant in Kalundborg.

Merck bogged down by slumping sales, but cuts deliver on profits

It has been a roller-coaster ride of a year for Merck, complete with M&A and corporate bloodletting intended to swing the company's numbers northward. Part of the drugmaker's ongoing turnaround plan could be paying off, as Merck announced third quarter earnings that beat analysts' expectations. But the company also reported slumping sales of some of its standout products due to hep C competitors and patent expirations, signaling more work in the months to come.

Novartis unloads last piece of vaccines puzzle to CSL for $275M

After a lengthy strategic review and a handful of divestments, Novartis' slim-down effort is finally coming to a close. The company has sold off its flu vaccines business--the only piece of the vaccines unit it hung onto after a multibillion-dollar April transaction with GlaxoSmithKline--to Australia's CSL.

Don't fire me, Sanofi CEO tells board, amid tussle over strategy

Sanofi CEO Chris Viehbacher has made some big moves since he took the helm in 2008. Now, he may have made one too many. According to a report from the French newspaper Les Echos, Viehbacher's future at Sanofi is in danger, with the French drugmaker's board increasingly unhappy with his decision-making.

Fed up with Allergan obstinance, Valeant CEO says he'd hike bid past $200 a share

Valeant CEO J. Michael Pearson is apparently sick of Allergan's mantra that his hostile bid "grossly undervalues" the company. While the bid is a good one, he contended in a Monday letter to the Botox-maker, Valeant will hike it further if it needs to--past $200 a share, in fact--and it's time for Allergan's board to come around.

Pfizer turns back Mylan's patent challenge to Sutent

Pfizer execs can sigh with relief now that a federal court has backed the company's patents on kidney cancer drug Sutent. The med has become increasingly important to Pfizer as sales of off-patent drugs have faded, and so it was alarming to the U.S. drugmaker when generics maker Mylan challenged the patent in 2010 and filed to make its own copy.

Yervoy, Sprycel, Eliquis jumps help Bristol-Myers beat Q3 estimates

The patent cliff may still be taking a toll on Bristol-Myers Squibb, but the company's Q3 sales haul was enough to impress analysts thanks to star performances from a few key new products.

EMA favors AstraZeneca's ovarian cancer drug Lynparza that FDA committee dissed

An FDA committee of experts this summer voted overwhelmingly against approval of AstraZeneca's new ovarian cancer treatment. But reviewers for the EMA gave it a nod for use on patients with platinum-sensitive ovarian cancer and BRCA mutations, FierceBiotech reports.

Shire poised to succeed as solo act post-AbbVie with solid Q3 earnings

Shire is riding solo after AbbVie called it quits on its proposed $52 billion acquisition, but the company isn't shedding too many tears. The Dublin-based drugmaker announced third-quarter earnings that beat analysts' expectations, leaving the door open for success post-AbbVie.

What does Pfizer's $11B buyback mean for the chances of an AstraZeneca bid?

Pfizer's $11 billion share buyback, announced late Thursday, gave investors something to focus on, rather than fretting about whether the company would renew its pursuit of AstraZeneca once the required cooling off period lapses in November. But some of them immediately started worrying about whether the buyback meant it was less likely Pfizer would do a big deal.

Actavis primed for another deal, or two, or maybe three

Allergan, Salix and Omega are all reportedly in Actavis' dealmaking sights, but which will the drugmaker go after? With an active M&A track record and deal veteran Brent Saunders at the helm, some analysts think the company could lock down more than one--but it won't necessarily be easy.

U.K. watchdogs back Bayer's Xarelto for heart attack patients

Bayer's Xarelto, which has been cruising along since it joined a new class of warfarin replacement therapies on the market, has faced a rare stumbling block in acute coronary syndrome--an indication the FDA has denied it on three separate occasions. But across the pond, it's picked up a nod in some ACS patients from the U.K.'s cost-effectiveness gatekeeper.

J&J Innovation taps Texas for its latest biotech startup incubator

Johnson & Johnson taking its network of biopharma incubators to Texas in an expansion of its Janssen Labs initiative.